Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ataluren Extension Study in Nonsense-Mutation Duchenne Muscular Dystrophy
NCT00759876Phase 2Terminated
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Aug 2008
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ataluren in Duchenne muscular dystrophy (DMD), sponsored by PTC Therapeutics, Inc.. Started Aug 2008; status: terminated.
02
Drugs
ataluren
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT00759876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00759876.